The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating the effectiveness of treatment cost calculation tool in improving patients' understanding of drug costs in advanced breast cancer: A multicenter, randomized controlled trial.
 
Kosho Yamanouchi
Expert Testimony - Kyowa Kirin
Travel, Accommodations, Expenses - Chugai Pharma; Lilly Japan
 
Sayaka Kuba
Speakers' Bureau - AstraZeneca; daiichi sankyo; Eisai; Kirin Pharmaceuticals; Lilly; Pfizer
Research Funding - Pfizer
 
Hiroki Moriuchi
Speakers' Bureau - Chugai Pharma; Lilly Japan; TAKATA Pharmaceutical Co., Ltd.
 
Shigeto Maeda
Honoraria - Daiichi Sankyo/UCB Japan; Eisai Europe; Kyowa Hakko Kirin; Lilly Japan; MSD Oncology
 
Megumi Matsumoto
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kirin Pharmaceuticals; Lilly Japan; Merck; Pfizer
Consulting or Advisory Role - Pfizer
 
Hiroshi Yano
No Relationships to Disclose
 
Masahiro Oikawa
No Relationships to Disclose
 
Michi Morita
No Relationships to Disclose
 
Momoko Akashi
No Relationships to Disclose
 
Ayako Fukushima
Employment - GlaxoSmithKline (I)
Honoraria - Kyowa Kirin
 
Aya Tanaka
No Relationships to Disclose
 
Eiko Inamasu
No Relationships to Disclose
 
Ryota Otsubo
No Relationships to Disclose
 
Keitaro Matsumoto
No Relationships to Disclose
 
Susumu Eguchi
Research Funding - Chugai Pharma; Eisai; Taiho Pharmaceutical; Tsumura & Co.